Research Library › Incretin & Amylin
Cagrilintide is a synthetic, long-acting analogue of amylin, a peptide hormone made by the same pancreatic beta cells that produce insulin. It was designed by chemists at Novo Nordisk in Denmark and described in the Journal of Medicinal Chemistry in 2021. As of 22 Oct 2026 cagrilintide is not approved anywhere, either alone or in CagriSema, its combination with semaglutide, which is under FDA review.
Key facts
| Type | Synthetic, lipidated amylin analogue (peptide) |
|---|---|
| Derived from | Human amylin (islet amyloid polypeptide) |
| First described | 2021, Journal of Medicinal Chemistry (Kruse et al., Novo Nordisk) |
| Developed by | Novo Nordisk, Denmark |
| Designed target | Amylin receptors |
| Regulatory status (Oct 2026) | Not FDA-approved; not approved elsewhere; CagriSema (with semaglutide) under FDA review, decision listed for Q4 2026 |
Who developed it
Cagrilintide was designed by medicinal chemists at Novo Nordisk in Denmark. The 2021 paper describing its development lists Thomas Kruse as lead author [1].
The hormone it is modeled on has a longer history. Amylin was identified in 1986–87, independently by Per Westermark’s group at Uppsala University in Sweden and by Garth Cooper, then an Oxford doctoral student, who went on to found Amylin Pharmaceuticals [2][3].
What it was designed to target
Amylin is a peptide hormone released alongside insulin by pancreatic beta cells [4]. Cagrilintide was designed to bind amylin receptors, the same receptors the natural hormone uses [1][5].
Natural human amylin is hard to work with because it tends to clump into amyloid fibers. Novo Nordisk’s chemists modified the sequence to make a more stable peptide and attached a fatty-acid side chain to extend its duration, a lipidation strategy the company had also used in semaglutide [1].
Why it was created
The first amylin analogue to reach the market was pramlintide, approved in the United States in 2005 as Symlin, from Amylin Pharmaceuticals, in an indication related to diabetes, as an adjunct to insulin [3][4]. Pramlintide is short-acting, which limited its practicality as a research and drug platform [1].
Novo Nordisk set out to build a long-acting amylin analogue, then paired it with its GLP-1 analogue semaglutide in a combination called CagriSema, investigated in a research program on chronic weight management. The rationale was to engage two complementary hormone pathways in one product [1][5].
Research timeline
- 1901: Amyloid deposits in the pancreatic islets of people with diabetes are first described [2].
- 1986–87: Amylin is identified as the main component of those deposits, in Sweden and England [2][3].
- 2005: FDA approves pramlintide (Symlin), the first amylin analogue [3][4].
- 2021: Novo Nordisk publishes the design of cagrilintide [1].
- Dec 2025: Novo Nordisk submits CagriSema (cagrilintide with semaglutide) to FDA [5].
- Q4 2026: FDA decision on CagriSema listed by Novo Nordisk; none announced as of 22 Oct 2026 [6].
Regulatory status as of October 2026
As of 22 Oct 2026, cagrilintide is not approved as a medicine in any country, either on its own or in combination. Novo Nordisk has developed it chiefly as one half of CagriSema, which it submitted to FDA on 18 December 2025 [5]. In its August 2026 financial report the company listed a U.S. decision on CagriSema for the fourth quarter of 2026; no decision had been announced as of 22 Oct 2026 [6].
Any future approval of CagriSema would cover that fixed combination product, not cagrilintide as a stand-alone peptide.
Cagrilintide is not named on the 2026 World Anti-Doping Agency Prohibited List; because it has no approval anywhere, the S0 (non-approved substances) category may apply [7].
Available from Kalibra Labs
Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.
Frequently asked questions
Who developed cagrilintide?
Cagrilintide was designed by Novo Nordisk in Denmark. The 2021 paper describing its development lists Thomas Kruse as lead author.
Is cagrilintide FDA approved?
No. As of 22 Oct 2026 cagrilintide is not approved anywhere. CagriSema, which combines it with semaglutide, is under FDA review with a decision listed for the fourth quarter of 2026.
What is the difference between cagrilintide and CagriSema?
Cagrilintide is a single long-acting amylin analogue. CagriSema is Novo Nordisk’s combination of cagrilintide with the GLP-1 analogue semaglutide.
What hormone is cagrilintide based on?
It is based on amylin, a peptide hormone co-released with insulin by pancreatic beta cells and first identified in 1986–87.
Sources
- Kruse T, Hansen JL, Dahl K, et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem. 2021;64:11183–11194. doi:10.1021/acs.jmedchem.1c00565. PMID 34288673. Link
- Westermark P. Amyloid in the islets of Langerhans: thoughts and some historical aspects. Ups J Med Sci. 2011;116(2):81–89. doi:10.3109/03009734.2011.573884. Link
- LabOnline / Life Scientist. FDA approves Amylin's diabetes drug (Symlin). 18 Mar 2005. Link
- PharmaTimes. Amylin wins US nod for Symlin. 18 Mar 2005. Link
- Novo Nordisk Inc. Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management. Press release, 18 Dec 2025. Link
- Novo Nordisk A/S. Financial report for the period 1 January 2026 to 30 June 2026 (milestone table: CagriSema US decision, Q4 2026). 4 Aug 2026. Link
- World Anti-Doping Agency. 2026 Prohibited List (S0 and S4.4). Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.
